We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+14.29%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.45B
AUM Growth
+$519M
(+27%)
Cap. Flow
-$25.5M
Cap. Flow
% of AUM
-1.04%
Top 10 Holdings %
Top 10 Hldgs %
32.76%
Holding
158
New
53
Increased
22
Reduced
25
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$90.2M |
| 2 |
Labcorp
LH
|
+$65.9M |
| 3 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$53.4M |
| 4 |
AbbVie
ABBV
|
+$51.8M |
| 5 |
ITMN
INTERMUNE INC
ITMN
|
+$35.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$43.2M |
| 2 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$41.1M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$37.6M |
| 4 |
Globus Medical
GMED
|
+$34.2M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.78% |
| 2 | Technology | 1.21% |
| 3 | Financials | 0.56% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurocrine Biosciences
NBIX
$17.4B
| $1.26M | 0.05% |
+77,994
| New | +$1.33M |
|
|
FURX
102
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
| $1.16M | 0.05% |
+13,340
| New | +$1.03M |
|
|
HOLX
103
DELISTED
Hologic
HOLX
| $914K | 0.04% |
+42,500
| New | +$917K |
|
104
Viatris
VTRS
$20.1B
| $855K | 0.03% |
17,500
-364,500
| -95% | -$17.7M |
|
|
MDVN
105
DELISTED
MEDIVATION, INC.
MDVN
| $805K | 0.03% |
+25,000
| New | +$922K |
|
106
Neurogene
NGNE
$732M
| $794K | 0.03% |
+3,119
| New | +$802K |
|
|
ELOS
107
DELISTED
Syneron Medical Ltd
ELOS
| $430K | 0.02% |
+34,518
| New | +$409K |
|
|
ACHN
108
DELISTED
Achillion Pharmaceuticals
ACHN
| $305K | 0.01% |
+92,804
| New | +$325K |
|
|
NVDQ
109
DELISTED
Novadaq Technologies Inc.
NVDQ
| $223K | 0.01% |
10,000
-110,010
| -92% | -$2.18M |
|
110
Amgen
AMGN
$198B
| – | – |
-10,000
| Closed | -$1.14M |
|
111
Arrowhead Research
ARWR
$10.2B
| – | – |
-142,017
| Closed | -$1.54M |
|
|
ASRT
112
DELISTED
Assertio
ASRT
| – | – |
-21,011
| Closed | -$13.3M |
|
113
Geron
GERN
$917M
| – | – |
-1,058,000
| Closed | -$4.74M |
|
|
114
Globus Medical
GMED
$10.4B
| – | – |
-1,694,472
| Closed | -$34.2M |
|
115
HCA Healthcare
HCA
$82B
| – | – |
-10,000
| Closed | -$477K |
|
|
116
Humana
HUM
$47.8B
| – | – |
-414,670
| Closed | -$43.2M |
|
117
Nuwellis
NUWE
$259K
| – | – |
0
| – | -$4.2M |
|
118
Option Care Health
OPCH
$3.41B
| – | – |
-17,506
| Closed | -$518K |
|
119
Prothena Corp
PRTA
$451M
| – | – |
-528,705
| Closed | -$14M |
|
|
SEM
120
DELISTED
Select Medical
SEM
| – | – |
-54,566
| Closed | -$341K |
|
121
Savara
SVRA
$1.12B
| – | – |
-20,946
| Closed | -$678K |
|
122
CALL
Teva Pharmaceuticals
TEVA
$36.5B
| – | – |
-350,000
| Closed | -$14M |
|
|
123
Teva Pharmaceuticals
TEVA
$36.5B
| – | – |
-5,000
| Closed | -$200K |
|
|
124
CALL
Viatris
VTRS
$20.1B
| – | – |
-150,000
| Closed | -$6.51M |
|
|
XOMA
125
DELISTED
Xoma
XOMA
| – | – |
-190,343
| Closed | -$27.6M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q1 2014 Portfolio in Review
As of Q1 2014, Deerfield Management held 158 positions worth $2.45B, up 27% from $1.93B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Deerfield Management's Q1 2014 filing shows 53 new, 22 increased, 25 reduced and 33 closed positions. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 2,428,569 shares worth $68.6M. The largest sale was Humana, an estimated $43.2M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 46% a quarter earlier, followed by Technology and Financials.
- Deerfield Management's largest Q1 2014 buy was Dicerna Pharmaceuticals, Inc.: 2,428,569 shares worth $68.6M.
- Deerfield Management added most to Insmed in Q1 2014, an estimated $18.3M increase.
- Deerfield Management's biggest Q1 2014 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $41.1M.
- Deerfield Management fully exited Humana in Q1 2014, selling an estimated $43.2M.
- Deerfield Management's ten largest holdings make up 33% of its $2.45B portfolio in Q1 2014.
- Deerfield Management opened 53 new positions and closed 33 in Q1 2014.
- Deerfield Management's portfolio value rose 27% quarter-over-quarter to $2.45B.
Based on Deerfield Management's 13F filing for Q1 2014, filed 15 May 2014.